Novel survivin inhibitor YM155 elicits cytotoxicity in glioblastoma cell lines with normal or deficiency DNA-dependent protein kinase activity.

@article{Lai2012NovelSI,
  title={Novel survivin inhibitor YM155 elicits cytotoxicity in glioblastoma cell lines with normal or deficiency DNA-dependent protein kinase activity.},
  author={Pei Chun Lai and Shu Chen and Shang Hsien Yang and Chuan Chu Cheng and Ted H. Chiu and Yen Ta Huang},
  journal={Pediatrics and neonatology},
  year={2012},
  volume={53 3},
  pages={199-204}
}
BACKGROUND Pediatric glioblastoma is a malignant disease with an extremely poor clinical outcome. Patients usually suffer from resistance to radiation therapy, so targeted drug treatment may be a new possibility for glioblastoma therapy. Survivin is also overexpressed in glioblastoma. YM155, a novel small-molecule survivin inhibitor, has not been examined for its use in glioblastoma therapy. METHODS The human glioblastoma cell line M059K, which expresses normal DNA-dependent protein kinase… CONTINUE READING